Results 141 to 150 of about 115,087 (327)

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

Current management of complicated infantile hemangiomas: Atenolol or Propranolol?

Iberoamerican Journal of Medicine, 2022
Ivan David Lozada-Martinez, Claudia Marcela Castañeda-Moreno, Juan Pablo Duran-Tabera, Gloria Patricia Crecian-Pérez   +3 more
doaj   +1 more source

Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma [PDF]

, 2013
Jennifer K. Wolter, Nikolaus E. Wolter, Alvaro Blanch, Teresa Partridge, Lynn S. Cheng, Daniel A. Morgenstern, Monika Podkowa, David R. Kaplan, Meredith S. Irwin   +8 more
openalex   +1 more source

PDE4D and PDE3B orchestrate distinct cAMP microdomains in 3T3‐L1 adipocytes

British Journal of Pharmacology, EarlyView.
Basal conditions: •Ins/PDE3B lowers cytoplasmic cAMP (cyt‐cAMP) without affecting plasma membrane cAMP (pm‐cAMP). •Insulin decreases lipid droplet cAMP (LD‐cAMP) independent of PDE3B. •FGF1/PDE4D modestly reduces both cyt‐ and pm‐cAMP, while PDE4D alone can modulate LD‐cAMP. ISO stimulation: •Ins/PDE3B has minimal impact on cyt‐cAMP.
Johannes Krier, David Spähn, David Arturo Juarez Lopez, Judith L. Nono, Judith Seigner, Lisa Jacob, Siegfried Ussar, Robert Lukowski, Andreas L. Birkenfeld, Gencer Sancar   +9 more
wiley   +1 more source

Blood Pressure (BP), but not Heart Rate (HR), is a Reliable Indicator for a Test Dose in Vascular Surgical Patients Receiving Beta-Adrenergic Antagonists

, 1995
Peter K. Schoenwald, David G. Whalley, Alexandru Gottlieb, Joseph V. Ryckman, Fanny Shutway   +4 more
openalex   +1 more source

Beta-Adrenergic Antagonist Tolerance in Amyloid Cardiomyopathy [PDF]

, 2022
Stuart Ramsell, Carlos Bermúdez, Cyril Ayuk Mbeng Takem Baiyee, Brandon Rodgers, Samir M. Parikh, Salem Almaani, Nidhi Sharma, Samantha LoRusso, Miriam Freimer, Elyse Redder, Naresh Bumma, Ajay Vallkati, Yvonne A. Efebera, Rami Kahwash, Courtney Campbell   +14 more
openalex   +1 more source

3,4‐Methylenedioxymethamphetamine (MDMA) does not induce robust psychomotor activation and 50‐kHz ultrasonic vocalisations in tryptophan hydroxylase 2 (Tph2)‐deficient rats lacking serotonin in the central nervous system

British Journal of Pharmacology, EarlyView.
Background and Purpose 3,4‐Methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, is a psychostimulant with entactogenic properties and known to induce arousal and euphoria. As an amphetamine derivate, MDMA acts on the monoamine systems in the brain and stimulates release of dopamine (DA), noradrenaline (NA) and serotonin (5‐HT), yet their ...
Tianhua Wang, Rainer K. W. Schwarting, Markus Wöhr   +2 more
wiley   +1 more source

Association of beta blockers and mortality in adults with septic shock: systematic review and meta-analysis of randomized clinical trial

Frontiers in Medicine
IntroductionSeptic shock still entails significant morbidity and mortality, with the heart being affected due to catecholamine overexpression and direct injury from sepsis.
Gustavo Adolfo Vásquez-Tirado, Claudia Vanessa Quispe-Castañeda, Edinson Dante Meregildo-Rodríguez, María Cuadra-Campos, Niler Manuel Segura-Plasencia, Yessenia Katherin Arbayza-Avalos, Hugo Nelson Alva-Guarniz, Wilson Marcial Guzmán-Aguilar, Petterson Zavaleta-Alaya   +8 more
doaj   +1 more source

Indobufen interacts with the sulphonylurea, glipizide, but not with the beta‐adrenergic receptor antagonists, propranolol and atenolol. [PDF]

, 1984
E Elvander‐Stahl, A. Melander, E Wahlin‐Boll   +2 more
openalex   +1 more source

Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder

Journal of Pharmacology and Experimental Therapeutics, 2017
J. D. Salvo, Hiroshi Nagabukuro, L. Wickham, Catherine Abbadie, Julie A. DeMartino, A. Fitzmaurice, Loise N. Gichuru, Alison A. Kulick, M. Donnelly, Nina Jochnowitz, Amanda L Hurley, A. Pereira, Anthony Sanfiz, G. Veronin, Katherine L. Villa, John W. Woods, Beata Zamlynny, Emanuel Zycband, G. Salituro, Tara L. Frenkl, Ann E. Weber, S. Edmondson, M. Struthers   +22 more
semanticscholar   +1 more source